Abstract Number: 0041 • ACR Convergence 2024
Disease Activity and Serological Inflammatory Markers Are Associated with TNF-a and IL-6-Induced Osteoclasts, but Not with RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Background/Purpose: We previously reported that a combination of TNF-α and IL-6 induces mouse osteoclast (OC)-like cells and human OCs with bone resorption activity [Arthritis &…Abstract Number: 0400 • ACR Convergence 2024
Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease in which osteoclastogenesis may play a critical role. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was shown…Abstract Number: 0937 • ACR Convergence 2024
A Novel Quantitative Method Reveals Bone-Structural Changes During Course of Inflammatory Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by both localized and generalized bone loss. The inhibition of Receptor Activator of Nuclear Factor…Abstract Number: 1204 • ACR Convergence 2024
Immunobased Profiling of Knee Osteoarthritis Patients to Predict Response to Regenerative Treatment with Autologous Blood-derivative Platelet-Rich Plasma Injection
Background/Purpose: Osteoarthritis (OA) is a degenerative musculoskeletal disease causing chronic disability and elevated social costs worldwide. Its multifactorial origin contributes to different OA phenotypes and…Abstract Number: 2134 • ACR Convergence 2024
PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo
Background/Purpose: Peroxisomal biogenesis factor 5 (PEX5) is essential for regulating peroxisome function by recognizing and transporting peroxisome target sequence receptor substrate proteins to peroxisomes. PEX5…Abstract Number: 2144 • ACR Convergence 2024
Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
Background/Purpose: CT-P41 has been developed as a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator…Abstract Number: 2563 • ACR Convergence 2024
Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…Abstract Number: 2441 • ACR Convergence 2023
Upregulation of RANKL in the Skin of Patients with Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the skin and joints. Circulating Osteoclast precursors (OCP) are elevated in the blood of…Abstract Number: 1679 • ACR Convergence 2023
Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Background/Purpose: We have previously demonstrated that a combination of TNF-a and IL-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in…Abstract Number: 1997 • ACR Convergence 2023
A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis
Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…Abstract Number: 2150 • ACR Convergence 2023
Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients
Background/Purpose: In Rheumatoid arthritis (RA), osteoclasts derived from CD14+ Monocytes are associated with a risk of progressive bone and joint destruction, which fundamentally impacts quality-of-life.…Abstract Number: L05 • ACR Convergence 2022
Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase
Background/Purpose: Erosive hand osteoarthritis (OA) is a disabling disease with limited therapeutic options. Denosumab, a Receptor Activator of Nuclear Factor kappa-b Ligand inhibitor, affects bone…Abstract Number: 0588 • ACR Convergence 2022
S-nitrosoglutathione Reductase (GSNOR) Regulates Osteoclast Differentiation
Background/Purpose: S-nitrosoglutathione (GSNO) reductase (GSNOR) is an enzyme which decomposes GSNO and downregulates protein S-nitrosylation. It has been reported that GSNOR KO mice have enhanced…Abstract Number: 0030 • ACR Convergence 2021
Interleukin-9 Enhances the Osteoclastogenesis in Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation leading to bone destruction. Bone erosion in RA results from excessive resorption…Abstract Number: 1472 • ACR Convergence 2021
Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis
Background/Purpose: We have previously reported that stimulation of mouse bone marrow–derived macrophages with a combination of tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) induces…
ACR Meeting Abstracts